Landaas & Company’s Inovio Pharmaceuticals INO Stock Holding History

Landaas & Company’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-2	Closed	–	–	177
2017 Q4	$0	Hold	2	–	–	﹤0.01%	350
2017 Q3	$0	Buy	+2	New	+$149	﹤0.01%	343

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Guggenheim Capital Chicago, Illinois $12.9B AUM 27.3% 1-Year Est. Return

Landaas & Company's INO Position: Q1 2018 in Review

Landaas & Company sold out of Inovio Pharmaceuticals (INO) in Q1 2018, closing a stake of 2 shares.

Landaas & Company first reported a position in INO in Q3 2017 and held it in 2 quarters. The position peaked at $0 in Q4 2017. 126 funds tracked by Wall St. Rank hold INO as of Q1 2018.

Landaas & Company reported no remaining Inovio Pharmaceuticals position as of Q1 2018 after selling out during the quarter.
Landaas & Company sold 2 Inovio Pharmaceuticals shares in Q1 2018.
Landaas & Company first reported a position in Inovio Pharmaceuticals in Q3 2017 and held it in 2 quarters.
Landaas & Company's Inovio Pharmaceuticals position peaked at $0 in Q4 2017.
126 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2018.

Based on Landaas & Company's 13F filing for Q1 2018, filed 14 May 2018.